title: Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation--a prospective analysis.
abstract: BACKGROUND
  Platelet transfusion refractoriness remains problematic in the management of patients who have undergone hematopoietic progenitor cell transplantation. Bone marrow transplantation itself is reported to be a relevant factor hampering efficient platelet transfusions. However, a prospective analysis assessing factors affecting platelet transfusion efficacy in the setting of hematopoietic progenitor cell transplantation has yet to be conducted.
  
  
  METHODS
  To identify factors independently influencing platelet transfusion efficacy after hematopoietic progenitor cell transplantation, a prospective study was performed to determine the effectiveness of platelet transfusions by estimating posttransfusion (16-hour) corrected count increments (CCI) in 42 consecutive patients (26 who received allogeneic transplants and 16 who received autologous transplants) with 439 available platelet transfusions.
  
  
  RESULTS
  The mean CCI and percentage of CCI <4500 for all transfusions were 6161.1 +/- 7775.2 per microL and 42.1 percent, respectively. Multiple linear regression analyses revealed high total bilirubin, total body irradiation, high serum tacrolimus, and high serum cyclosporin A to be major factors independently predicting a lower CCI. HLA antibodies with restricted specificity and platelet antibodies were detected transiently in 17 and 14 percent of the patients, respectively. The presence of these antibodies was not, however, associated with a poor response to platelet transfusions.
  
  
  CONCLUSIONS
  Platelet transfusion efficacy in hematopoietic progenitor cell transplant recipients is markedly influenced by clinical factors specific to the procedure as well as those already recognized in other settings. Alloimmunization is not, however, a major factor associated with a poor response to platelet transfusions after this procedure.
authors.affiliation: Blood Center, Department of Medicine, School of Medicine, Keio University, Tokyo, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Ishida
authors.forename: M
authors.initials: M
authors.lastname: Handa
authors.forename: M
authors.initials: M
authors.lastname: Wakui
authors.forename: S
authors.initials: S
authors.lastname: Okamoto
authors.forename: M
authors.initials: M
authors.lastname: Kamakura
authors.forename: Y
authors.initials: Y
authors.lastname: Ikeda
mesh_terms: D000293:Adolescent; D000328:Adult; D001663:Bilirubin / Q000097:blood; D016572:Cyclosporine / Q000097:blood; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D017713:Platelet Transfusion; D011446:Prospective Studies; D016559:Tacrolimus / Q000097:blood; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
chemical_list: D006680:HLA Antigens; D007518:Isoantibodies; D016572:Cyclosporine; D001663:Bilirubin; D016559:Tacrolimus